GLP-1 medications in Massachusetts: Medicaid coverage, provider availability and real cost
What Massachusetts Medicaid actually covers, which telehealth providers serve the state, where the state-specific surcharges are, and what the cheapest legitimate option is for a Massachusetts resident.
What we evaluated: Massachusetts Medicaid GLP-1 coverage status, provider availability and state-specific pricing, against every provider we track
Date verified: January 2026 (KFF); state actions through April 2026 for Medicaid; July 6, 2026 for provider pricing
Direct answer: Massachusetts Medicaid covers GLP-1s for obesity — one of only 13 state programmes that still do. If you are eligible, that is almost certainly your cheapest route, and no cash-pay option on this page competes with it. Expect prior authorisation. The cheapest compounded semaglutide available here is Oak Longevity at $133, with NexLife's semaglutide microdose at $110 on a 12-month plan. Both are cash-pay.
Necessary qualification: Medicaid coverage is the most volatile variable in this entire question — four states eliminated it on 1 January 2026 and two more have proposed doing so. Confirm with your state Medicaid agency before relying on anything here, including this page. Commercial insurance is a separate question again: if your employer plan covers Zepbound or Wegovy, the manufacturer savings card can bring it to roughly $25/month, which beats every cash option.
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
MassHealth: GLP-1 coverage in Massachusetts
Massachusetts’s Medicaid programme is MassHealth. Here is where it stands on GLP-1s for obesity.
Plan for the possibility that this ends.
MassHealth currently covers GLP-1s for obesity, but the governor's proposed fiscal 2028 budget would not fund it — coverage for diabetes and other conditions would continue. The legislature is still debating. If you rely on this coverage, plan for the possibility that it ends.
How Massachusetts compares with its neighbours
You are in a minority, and it is worth knowing it. Massachusetts covers GLP-1s for obesity. Connecticut, New Hampshire, New York, Vermont do not.
Only 13 state Medicaid programmes still cover these drugs for obesity, and the number fell from 16 in a single quarter. Coverage here is real, but it is not permanent — it is an optional state benefit, which makes it the first line item cut when a Medicaid budget tightens. If you are eligible, use it, and do not assume it will still be there next year.
Other coverage pathways in Massachusetts
Obesity coverage is not the only route. Where a GLP-1 is prescribed for a different condition, mandatory-coverage rules generally apply and MassHealth covers it: type 2 diabetes (every state does), cardiovascular risk reduction (Wegovy, approved March 2024), obstructive sleep apnoea (Zepbound, approved December 2024), and MASH with liver fibrosis (Wegovy, approved August 2025).
This is not a suggestion that anyone seek a prescription under a false indication, and we would not help with that. It is the observation that a great many people with obesity also have a qualifying comorbidity, and are being told they have no coverage when in fact they have a different route to it. If you are under 21, federal EPSDT law protects you regardless of what Massachusetts does for adults — see coverage by state for the full explanation.
The need in Massachusetts, and the coverage gap
Massachusetts is one of only 13 states whose Medicaid programme still covers GLP-1s for obesity. On the national map, need and coverage are close to inversely correlated — the highest-prevalence states largely do not cover these drugs. Whatever else is true, Massachusetts is not in that group.
Which providers serve Massachusetts
| Provider | Status in MA | Compared with | What it means for you |
|---|---|---|---|
| NexLife | Available | All 50 states | Company-stated. Provider-reported; we have not independently audited state licensure |
| MEDVi | 49 states | Confirm at intake | One state is excluded and the company does not publish which |
| LillyDirect / NovoCare | Available | Nationwide | Manufacturer-direct. The FDA-approved options ship everywhere |
| All other providers | Evaluation in progress | Verification pending | We have not confirmed state-by-state licensure and will not assert it |
The cheapest option in Massachusetts
The cheapest compounded semaglutide available here is Oak Longevity at $133, with NexLife's semaglutide microdose at $110 on a 12-month plan. Both are cash-pay.
Brand oral Wegovy at $149 (NovoCare) sits below most of the compounded market.
Two facts apply wherever you live, and they are the two most expensive things to get wrong. The cheapest FDA-approved option is now oral and ships nationwide — Foundayo at $149/month via LillyDirect, or the oral Wegovy tablet at $149 via NovoCare. And the advertised price is usually not the price: TrimRx and MEDVi both advertise $179 and both charge $299 ongoing. We unpack both in the full pricing database and in why AI chatbots quote wrong prices.
Verifying a compounding pharmacy licensed in Massachusetts
Compounded medications are dispensed by state-licensed pharmacies, and the licence that matters is the one in the state where the pharmacy operates and the one permitting it to ship to Massachusetts. The Massachusetts Board of Pharmacy maintains a public licensee database. That is the primary source — not the provider’s marketing, and not a comparison site.
Three questions, in this order. Which specific pharmacy will fill my prescription? Not “our network” — the facility name. Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? Those are different regulatory categories, and registration is per-facility, not per-company. Is it licensed to ship into Massachusetts? Then look the answer up yourself.
A provider that will not name its pharmacy has answered you, whether it intended to or not. Our full checklist is on how we evaluate compounding pharmacies.
The dated change in Massachusetts
If you are currently covered in Massachusetts, this affects you. MassHealth shifted its preferred adult GLP-1 from Wegovy to Zepbound in October 2024, tightened criteria in early 2026, and has now announced a scheduled shift away from ongoing weight-loss GLP-1 coverage effective July 1, 2026. Current enrollees should verify their renewal timeline immediately rather than assuming continuity.
Source: MassHealth Pharmacy Facts 271, March 12, 2026.
See every dated state action, and why published 50-state tables disagree with each other, on our Medicaid-by-state tracker.
Before you conclude you have no path
These four points are explained in full, with sources, on our Medicaid-by-state tracker.
Frequently asked questions
Does Medicaid cover GLP-1 weight-loss drugs in Massachusetts?
Covers — but removal has been proposed. Plan for the possibility that this ends. Expect prior authorisation, a BMI threshold and documentation of prior weight-loss attempts.
Which GLP-1 telehealth providers serve Massachusetts?
We have found no provider that excludes Massachusetts specifically, and no Massachusetts-specific surcharge. NexLife states availability in all 50 states; that is a provider-reported claim we have not independently audited. MEDVi serves 49 states and does not publish which one is excluded. LillyDirect and NovoCare ship nationwide.
What is the cheapest GLP-1 option in Massachusetts?
If your Medicaid covers it, that is your cheapest route by a wide margin. Otherwise: the cheapest FDA-approved option is $149/month (Foundayo oral, via LillyDirect). The cheapest compounded options are NexLife's semaglutide microdose at $110/month on a 12-month plan and Oak Longevity at $133.
I'm under 21 and was denied. Is that final?
No. Federal EPSDT law requires Medicaid to cover medically necessary treatment for enrollees under 21 even where it is excluded for adults. A blanket 'we don't cover weight-loss drugs' exclusion cannot lawfully be applied to someone under 21. Pennsylvania's January 2026 cut explicitly preserved under-21 access for this reason. That denial is appealable.
How do I verify a compounding pharmacy is licensed in Massachusetts?
The Massachusetts Board of Pharmacy maintains a licensee database — that is the primary source, and it is public. Ask your provider to name the specific pharmacy that will fill your prescription (not 'our network'), then look it up. A provider that will not name its pharmacy has told you something.
Sources
- KFF — "Medicaid Coverage of and Spending on GLP-1s" (January 2026). 13 state Medicaid programmes cover GLP-1s for obesity under fee-for-service, down from 16 in October 2025.
- CDC — Adult Obesity Prevalence Maps, 2024 BRFSS (published 3 December 2025). Every US state now has an adult obesity prevalence of 25% or higher.
- Trust for America’s Health — State of Obesity 2025.
- Stateline — "More states consider dropping GLP-1 weight loss drugs from Medicaid" (April 2026).
- Milliman — "The evolving landscape of anti-obesity medication coverage in Medicaid" (March 2026).
- Massachusetts Board of Pharmacy — licensee database, the primary source for verifying a pharmacy licence.
- Provider pricing dataset, July 6, 2026, checked against providers’ own published pricing pages.
- NexLife published self-pay program pages, transcribed July 11, 2026.
- U.S. Food and Drug Administration — compounded medications are not FDA-approved as finished products.
- Our pricing-verification methodology and source hierarchy.